{"product_id":"snes-vrio-analysis","title":"SenesTech, Inc. (SNES): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eDiscover the true engine behind SenesTech, Inc. (SNES)'s competitive edge! This VRIO analysis cuts straight to the core, revealing precisely which of its resources are truly Valuable, Rare, Inimitable, and Organized for success. Uncover the secrets to their sustainable advantage - or the critical gaps they must address - by diving into the full breakdown below.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSenesTech, Inc. (SNES) - VRIO Analysis: Proprietary Fertility Control Technology (IP)\n\u003c\/h2\u003e\n\n\u003cp\u003eYou're looking at the core intellectual property of SenesTech, Inc. (SNES) - the science behind their fertility control products. This technology is what allows them to operate in a space where traditional, lethal toxins are increasingly unwelcome. The market is clearly responding, with Evolve® Rodent Birth Control sales growing 77% year-over-year in Q3 2025, making up 85% of the company's record $690,000 in third-quarter revenue.\u003c\/p\u003e\n\n\u003ch\u003eValue: Non-Lethal Market Access\u003c\/h\u003e\n\u003cp\u003eThe technology creates a non-lethal, sustainable pest management solution, which is a massive value proposition for municipalities, food processors, and environmentally conscious consumers wary of poisons. This is why the Evolve line is driving such strong top-line growth, with Q2 2025 revenue up 36% year-over-year and Q3 2025 revenue up 43% year-over-year. The EPA designation of Evolve as a minimum-risk pesticide under FIFRA Section 25(b) is a direct translation of this value into regulatory compliance, opening doors where ContraPest®, which requires an RUP license in Connecticut, faces hurdles.\u003c\/p\u003e\n\n\u003ch\u003eRarity: Unique Regulatory Status\u003c\/h\u003e\n\u003cp\u003eThe core science behind their specific, EPA-compliant rodent fertility control is currently unique in the market. Specifically, being the only manufacturer of EPA-registered contraceptive products for rats (ContraPest®) and having the minimum-risk designation for Evolve products makes this IP rare. No other widely available, proven product offers this combination of efficacy and non-lethality backed by federal clearance. This rarity is what allows them to command a record gross profit margin of 65.4% in Q2 2025, though it settled back to 62.8% in Q3 2025.\u003c\/p\u003e\n\n\u003ch\u003eImitability: High Barrier, Not Impossible\u003c\/h\u003e\n\u003cp\u003eImitability is medium. While the underlying science is complex and requires significant R\u0026amp;D investment - R\u0026amp;D expenses were $418,000 in Q1 2025 - competitors can invest heavily to develop alternatives. The real barrier isn't just the chemistry; it's the regulatory pathway. Gaining EPA registration or minimum-risk exemption is a time-consuming, expensive process that acts as a significant moat, even if the core science is eventually reverse-engineered or surpassed. Still, a well-funded rival could chip away at this over several years.\u003c\/p\u003e\n\n\u003ch\u003eOrganization: Focus on Scaling Cash Runway\u003c\/h\u003e\n\u003cp\u003eThe company is actively building its defensible market position on science and IP protection, evidenced by its strategic focus on the higher-margin Evolve products. Organizationally, they are managing cash to buy time for scaling. As of Q3 2025, cash and short-term investments stood at $10.2 million, which management believes provides an operating runway through the foreseeable future, possibly into 2027. However, the organization still posts net losses - $1.3 million in Q3 2025 - meaning they need to convert this IP into consistent, scaled profitability, which requires more than just having the technology.\u003c\/p\u003e\n\n\u003ch\u003eCompetitive Advantage: Temporary, Pending Scale\u003c\/h\u003e\n\u003cp\u003eThe competitive advantage is currently \u003cstrong\u003eTemporary\u003c\/strong\u003e. The science is the foundation, but without sustained regulatory wins in all key markets and significant market adoption that drives consistent operating profit, it remains vulnerable. The company needs to consistently surpass the quarterly sales level of about $1.5 million to reach breakeven, far above the $690,000 achieved in Q3 2025. Until they achieve that scale and prove the model is self-sustaining, the advantage is temporary. The recent launch on Lowes.com is a step toward that scale, but it's not yet realized.\u003c\/p\u003e\n\n\u003cp\u003eHere’s the quick math on where the IP currently stands:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO Dimension\u003c\/td\u003e\n\u003ctd\u003eAssessment\u003c\/td\u003e\n\u003ctd\u003eKey Supporting Data (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eEvolve products are 85% of Q3 revenue.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eOnly manufacturer of EPA-registered\/compliant fertility control.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003eMedium\u003c\/td\u003e\n\u003ctd\u003eComplex science, but regulatory hurdles slow direct imitation.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eIn Progress\u003c\/td\u003e\n\u003ctd\u003eCash of $10.2 million provides runway, but net losses persist.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003eTemporary\u003c\/td\u003e\n\u003ctd\u003eMust scale quarterly revenue past $1.5 million to sustain advantage.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eWhat this estimate hides is the risk associated with the accumulated deficit, which stood at $137.762 million as of Q1 2025, meaning external financing remains a key organizational dependency.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eIdentify next key regulatory approval date.\u003c\/li\u003e\n\u003cli\u003eModel cash burn against $10.2 million balance.\u003c\/li\u003e\n\u003cli\u003eBenchmark Q4 2025 revenue against $1.5 million breakeven target.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSenesTech, Inc. (SNES) - VRIO Analysis: EPA-Compliant Registration Status\n\u003c\/h2\u003e\n\u003cp\u003e\nValue: This regulatory approval is a massive moat, allowing sales where lethal rodenticides face bans or increasing scrutiny.\n\u003c\/p\u003e\n\u003cp\u003e\nRarity: High. Being the only manufacturer of EPA-compliant Rodent Birth Control™ products is a significant, hard-to-replicate advantage. Evolve® Rodent Birth Control product sales grew \u003cstrong\u003e77%\u003c\/strong\u003e year-over-year in Q3 2025, representing \u003cstrong\u003e85%\u003c\/strong\u003e of total revenue for that quarter, which was \u003cstrong\u003e$690,000\u003c\/strong\u003e.\n\u003c\/p\u003e\n\u003cp\u003e\nImitability: High. Replicating this requires years of testing, data submission, and navigating the EPA process, which is a huge time and cost sink for rivals.\n\u003c\/p\u003e\n\u003cp\u003e\nOrganization: Yes. Management explicitly cites regulatory trust as a key part of their defensible position.\n\u003c\/p\u003e\n\u003cp\u003e\nCompetitive Advantage: Sustained. Regulatory barriers to entry in this space are extremely high, providing a durable advantage as long as compliance is maintained.\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct\u003c\/td\u003e\n\u003ctd\u003eRegulatory Status Detail\u003c\/td\u003e\n\u003ctd\u003eGeographic Reach Data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eContraPest®\u003c\/td\u003e\n\u003ctd\u003eRegistered federally as a General Use Product; requires RUP license in Connecticut.\u003c\/td\u003e\n\u003ctd\u003eRegistered in all \u003cstrong\u003e50\u003c\/strong\u003e states, with \u003cstrong\u003e49\u003c\/strong\u003e approving removal of RUP designation, plus the District of Columbia and five major U.S. territories.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEvolve™\u003c\/td\u003e\n\u003ctd\u003eQualifies as a minimum risk pesticide under FIFRA Section 25(b) and is exempt from registration by the U.S. Environmental Protection Agency.\u003c\/td\u003e\n\u003ctd\u003eAuthorized to sell in \u003cstrong\u003e30\u003c\/strong\u003e states as of the 10-K filing date referencing data as of December 31, 2023.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\nThe regulatory landscape supports the business model through specific market dynamics:\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eEvolve® Rat product contributed approximately \u003cstrong\u003e52%\u003c\/strong\u003e of Q3 2024 revenue.\u003c\/li\u003e\n\u003cli\u003eE-commerce revenue increased \u003cstrong\u003e55%\u003c\/strong\u003e year-over-year in Q3 2025.\u003c\/li\u003e\n\u003cli\u003eMunicipal revenue grew \u003cstrong\u003e139%\u003c\/strong\u003e year-over-year in Q3 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSenesTech, Inc. (SNES) - VRIO Analysis: Evolve Product Line Dominance\n\u003c\/h2\u003e\n\u003cp\u003e\nEvolve Product Line Dominance\n\u003c\/p\u003e\n\u003cp\u003e\n\u003cstrong\u003eValue\u003c\/strong\u003e: The Evolve products (Rat\/Mouse) are the primary growth engine, making up \u003cstrong\u003e85%\u003c\/strong\u003e of Q3 2025 revenue, which totaled \u003cstrong\u003e$690,000\u003c\/strong\u003e for the quarter. The gross profit margin for Q3 2025 was \u003cstrong\u003e62.8%\u003c\/strong\u003e.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003cstrong\u003eRarity\u003c\/strong\u003e: No. Other companies have product lines, but the market share and growth rate of Evolve are notable. The legacy ContraPest product line decreased by \u003cstrong\u003e31%\u003c\/strong\u003e year-over-year in Q3 2025, now representing only \u003cstrong\u003e15%\u003c\/strong\u003e of total revenue.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003cstrong\u003eImitability\u003c\/strong\u003e: Low. Competitors can launch similar products, but displacing Evolve’s current \u003cstrong\u003e77%\u003c\/strong\u003e Year-over-Year (YoY) growth rate is tough once adoption takes hold.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003cstrong\u003eOrganization\u003c\/strong\u003e: Yes. Sales and marketing efforts are clearly focused on driving Evolve adoption across all channels. The company reported cash and short-term investments of \u003cstrong\u003e$10.2 million\u003c\/strong\u003e as of September 30, 2025.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e: Temporary. Strong product momentum is great, but it can erode if a superior, cheaper, or more convenient alternative emerges. The Adjusted EBITDA loss improved to a company record of \u003cstrong\u003e$1.2 million\u003c\/strong\u003e in Q3 2025.\n\u003c\/p\u003e\n\u003cp\u003e\nKey financial metrics for the Evolve-driven Q3 2025 performance:\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eAmount\/Percentage\u003c\/th\u003e\n\u003cth\u003eComparison\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenue (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$690,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUp \u003cstrong\u003e43%\u003c\/strong\u003e YoY from $482,000 in Q3 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEvolve Revenue Share\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e85%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUp from \u003cstrong\u003e79%\u003c\/strong\u003e of total revenue in Q1 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEvolve YoY Growth\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e77%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDriven by new product adoption\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Profit Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e62.8%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSlightly below Q2 2025's \u003cstrong\u003e65.4%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted EBITDA Loss\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eBest in company history\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\nChannel performance highlights for Q3 2025 demonstrate organizational focus:\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eE-commerce sales accounted for \u003cstrong\u003e54%\u003c\/strong\u003e of Q3 revenue, increasing \u003cstrong\u003e55%\u003c\/strong\u003e YoY.\u003c\/li\u003e\n\u003cli\u003eMunicipal revenue grew \u003cstrong\u003e139%\u003c\/strong\u003e YoY.\u003c\/li\u003e\n\u003cli\u003eBrick-and-mortar retail sales increased \u003cstrong\u003e254%\u003c\/strong\u003e YoY.\u003c\/li\u003e\n\u003cli\u003ePest Management Professionals (PMPs) accounted for approximately \u003cstrong\u003e20%\u003c\/strong\u003e of revenue, showing \u003cstrong\u003e29%\u003c\/strong\u003e YoY growth.\u003c\/li\u003e\n\u003cli\u003eNet Loss for the quarter was \u003cstrong\u003e$1.3 million\u003c\/strong\u003e, narrowing from $1.5 million in Q3 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSenesTech, Inc. (SNES) - VRIO Analysis: Multi-Channel Distribution Network\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides diversified revenue streams, with e-commerce at \u003cstrong\u003e55%\u003c\/strong\u003e YoY growth, municipal at \u003cstrong\u003e139%\u003c\/strong\u003e YoY, and retail at \u003cstrong\u003e254%\u003c\/strong\u003e YoY in Q3 2025. Total Q3 2025 revenue was \u003cstrong\u003e$690,000\u003c\/strong\u003e, a \u003cstrong\u003e43%\u003c\/strong\u003e increase year-over-year. Evolve® Rodent Birth Control product sales grew \u003cstrong\u003e77%\u003c\/strong\u003e year-over-year, representing \u003cstrong\u003e85%\u003c\/strong\u003e of total revenue, with a gross profit margin of \u003cstrong\u003e62.8%\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eThe multi-channel approach diversifies risk away from a single sales vector, with e-commerce contributing \u003cstrong\u003e54%\u003c\/strong\u003e of Q3 2025 sales.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eDistribution Channel\u003c\/th\u003e\n\u003cth\u003eQ3 2025 YoY Growth\u003c\/th\u003e\n\u003cth\u003eQ3 2025 Revenue Share (Approx.)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eE-commerce\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e55%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e54%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMunicipal\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e139%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNot explicitly stated as a percentage of total revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetail (Brick-and-Mortar)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e254%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eImplied remainder after E-commerce and PMPs (PMPs were 19% of revenue)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePest Management Professionals (PMPs)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e29%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e19%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eNo. Many pest control firms have distribution, but SenesTech, Inc.'s specific traction across these diverse channels is unique, particularly the combination of high growth in municipal contracts alongside e-commerce dominance. The \u003cstrong\u003e139%\u003c\/strong\u003e YoY growth in municipal revenue is a notable differentiator.\u003c\/p\u003e\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eMedium. Building out relationships with Amazon, Lowe's.com, Ace Hardware, and municipal contracts takes time and trust. The company is actively leveraging expanded adoption by Ace Hardware, which more than doubled its coverage area during the quarter, and follow-on orders from Bradley Caldwell, a wholesaler serving over \u003cstrong\u003e8,000\u003c\/strong\u003e retail locations in the Northeast.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eE-commerce growth driven by double-digit growth in Amazon sales.\u003c\/li\u003e\n\u003cli\u003eProducts are now available on Lowe's.com, with discussions for a potential \u003cstrong\u003e100\u003c\/strong\u003e-store in-store test.\u003c\/li\u003e\n\u003cli\u003eMunicipal revenue growth driven by expanded deployments in New York City and Chicago.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eYes. The company is actively managing and expanding its six-channel strategy. The company reported a strong cash balance of over \u003cstrong\u003e$10.2 million\u003c\/strong\u003e at the end of September 2025, providing an operating runway.\u003c\/p\u003e\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eSustained. Deep channel penetration, especially in regulated municipal areas, creates high switching costs for customers. The shift to the higher-margin Evolve product line (\u003cstrong\u003e85%\u003c\/strong\u003e of revenue) reinforces the value proposition over legacy products.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSenesTech, Inc. (SNES) - VRIO Analysis: High Gross Margin Profile\n\u003c\/h2\u003e\n\u003cp\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003c\/p\u003e\u003cp\u003eThe shift to Evolve has driven gross margins to \u003cstrong\u003e62.8%\u003c\/strong\u003e in Q3 2025, significantly improving the path to profitability. Q3 2025 Revenue was \u003cstrong\u003e$690,000\u003c\/strong\u003e, with Evolve® Rodent Birth Control product sales representing \u003cstrong\u003e85%\u003c\/strong\u003e of total revenue, growing \u003cstrong\u003e77%\u003c\/strong\u003e year-over-year. Gross Profit Dollars for Q3 2025 were \u003cstrong\u003e$433,000\u003c\/strong\u003e, up from \u003cstrong\u003e$315,000\u003c\/strong\u003e in Q3 2024. Cash and short-term investments totaled \u003cstrong\u003e$10.2 million\u003c\/strong\u003e at the end of September 2025.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003ctd\u003eQ3 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$690,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$482,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Profit Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e62.8%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e(Not explicitly stated, but Q2 2024 was 54.2%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Profit Dollars\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$433,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$315,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEvolve % of Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e85%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e(Lower than 85%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003c\/p\u003e\u003cp\u003eNo. High margins exist in specialty chemicals, but this margin level is new for the company’s overall mix. The Q2 2025 gross margin was \u003cstrong\u003e65.4%\u003c\/strong\u003e. The company estimates its quarterly revenue breakeven point to be around \u003cstrong\u003e$1.5 million\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003c\/p\u003e\u003cp\u003eMedium. Competitors can try to price aggressively or launch higher-margin products, but this margin is tied to the Evolve formulation. Evolve product sales grew \u003cstrong\u003e94%\u003c\/strong\u003e year-over-year in Q2 2025.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003c\/p\u003e\u003cp\u003eYes. Management tracks gross profit dollars as a key metric to achieving cash flow breakeven. Adjusted EBITDA loss improved to \u003cstrong\u003e$1.2 million\u003c\/strong\u003e in Q3 2025, compared to \u003cstrong\u003e$1.4 million\u003c\/strong\u003e in Q3 2024. Operating expenses were down \u003cstrong\u003e4%\u003c\/strong\u003e compared to last year and down \u003cstrong\u003e12%\u003c\/strong\u003e sequentially in Q3 2025.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eE-commerce revenue increased \u003cstrong\u003e55%\u003c\/strong\u003e year-over-year in Q3 2025, representing \u003cstrong\u003e54%\u003c\/strong\u003e of Q3 sales.\u003c\/li\u003e\n\u003cli\u003eMunicipal revenue grew \u003cstrong\u003e139%\u003c\/strong\u003e year-over-year in Q3 2025.\u003c\/li\u003e\n\u003cli\u003eRetail sales rose \u003cstrong\u003e254%\u003c\/strong\u003e year-over-year in Q3 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003c\/p\u003e\u003cp\u003eTemporary. While excellent now, sustained profitability requires maintaining this margin while scaling sales volume. The company has \u003cstrong\u003e23\u003c\/strong\u003e employees.\u003c\/p\u003e\n\n\n\u003cbr\u003e\u003ch2\u003eSenesTech, Inc. (SNES) - VRIO Analysis: Automated Manufacturing Facility\n\u003c\/h2\u003e\n\u003cp\u003eThe analysis below focuses on the strategic asset of the Automated Manufacturing Facility.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eThe transition to a new, automated manufacturing facility was completed in \u003cstrong\u003eJuly 2025\u003c\/strong\u003e. This investment is explicitly aimed at meeting the growing demand for Evolve products and is projected to support annual revenue of approximately \u003cstrong\u003e$10 million\u003c\/strong\u003e. The automation is designed to drive further gross margin improvement through efficiency gains. This efficiency is evidenced by the Gross Profit Margin expanding to \u003cstrong\u003e65.4%\u003c\/strong\u003e in Q2 2025, up from \u003cstrong\u003e54.2%\u003c\/strong\u003e in Q2 2024. The resulting gross profit in Q2 2025 was \u003cstrong\u003e$409,000\u003c\/strong\u003e, a \u003cstrong\u003e64%\u003c\/strong\u003e year-over-year rise. Evolve products, the primary driver of this margin expansion, represented \u003cstrong\u003e83%\u003c\/strong\u003e of total Q2 2025 revenue of \u003cstrong\u003e$625,000\u003c\/strong\u003e. \u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eQ2 2024\u003c\/td\u003e\n\u003ctd\u003eQ2 2025\u003c\/td\u003e\n\u003ctd\u003eChange\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Profit Margin (GAAP)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e54.2%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e65.4%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e+11.2 percentage points\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$459,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$625,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e+36%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Profit Dollars (GAAP)\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$409,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e+64% YoY\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eManufacturing plants are common assets. However, a facility recently upgraded with specific automation tailored for the specialized Evolve rodent birth control bait product is less common in the immediate competitive landscape.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eReplicating this capability presents a \u003cstrong\u003eMedium\u003c\/strong\u003e barrier. Competitors possess the ability to build or contract for general manufacturing capacity. Replicating the specific, proprietary automation implemented for the Evolve bait formulation and production process is not trivial and requires significant capital and process development time.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eYes\u003c\/strong\u003e. The investment in the automated facility was made specifically to support current and future Evolve demand, aligning with the company's strategic focus. Organizational alignment is further suggested by the reduction of the breakeven revenue threshold to \u003cstrong\u003e$7 million\u003c\/strong\u003e annually, supported by operational efficiencies and cost discipline.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCash and short-term investments totaled \u003cstrong\u003e$11.2 million\u003c\/strong\u003e as of August 5, 2025, providing an operating runway through the end of \u003cstrong\u003e2027\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe company has demonstrated organizational focus by having Evolve products account for \u003cstrong\u003e83%\u003c\/strong\u003e of Q2 2025 revenue.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eTemporary\u003c\/strong\u003e. The facility provides a short-term cost advantage and improved capacity utilization, which translates to a higher gross margin (e.g., \u003cstrong\u003e65.4%\u003c\/strong\u003e in Q2 2025). This advantage is temporary until competitors can expand their own capacity or replicate the efficiency gains through their own capital investments.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSenesTech, Inc. (SNES) - VRIO Analysis: Strong Cash Position\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Ended Q3 2025 with \u003cstrong\u003e$10.2 million\u003c\/strong\u003e in cash and short-term investments. This balance supports the company's operating runway, with management previously indicating sufficient funding through the end of \u003cstrong\u003e2027\u003c\/strong\u003e based on prior financing activities and run rate.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFinancial Metric\u003c\/th\u003e\n\u003cth\u003eAmount (Q3 2025)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash \u0026amp; Short-Term Investments\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$10.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$690,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted EBITDA Loss (Record Low)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating Cash Flow (TTM)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-$5.30 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e \u003cstrong\u003eNo.\u003c\/strong\u003e Many public companies hold cash, but this specific amount provides a runway extending past the projected cash flow breakeven point, which management estimates requires a little over \u003cstrong\u003e$1.5 million\u003c\/strong\u003e in quarterly revenue.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e \u003cstrong\u003eLow.\u003c\/strong\u003e Cash is fungible, but this specific balance is the result of past financing events, including warrant exercises that generated proceeds such as \u003cstrong\u003e$6.3 million\u003c\/strong\u003e and \u003cstrong\u003e$4.4 million\u003c\/strong\u003e in separate transactions, combined with current burn rate management reflected in the record low Adjusted EBITDA loss of \u003cstrong\u003e$1.2 million\u003c\/strong\u003e for the quarter.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e \u003cstrong\u003eYes.\u003c\/strong\u003e Management is utilizing this cash position to bridge operations to profitability without the immediate necessity of a dilutive equity raise, focusing on achieving the breakeven revenue target of over \u003cstrong\u003e$1.5 million\u003c\/strong\u003e per quarter.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e \u003cstrong\u003eSustained.\u003c\/strong\u003e A secure runway reduces execution risk associated with capital constraints and allows management to concentrate resources purely on scaling growth initiatives, a significant advantage over cash-strapped peers in the sector.\u003c\/p\u003e\n\u003cp\u003eThe operational performance supporting this cash position includes:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eEvolve Rodent Birth Control products accounted for \u003cstrong\u003e85%\u003c\/strong\u003e of total revenue in Q3 2025.\u003c\/li\u003e\n\u003cli\u003eYear-over-year revenue growth of \u003cstrong\u003e43%\u003c\/strong\u003e in Q3 2025, reaching \u003cstrong\u003e$690,000\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eGross Margin maintained at approximately \u003cstrong\u003e63%\u003c\/strong\u003e in Q3 2025.\u003c\/li\u003e\n\u003cli\u003eOperating expenses were down \u003cstrong\u003e4%\u003c\/strong\u003e compared to the prior year.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSenesTech, Inc. (SNES) - VRIO Analysis: Category Leadership and Awareness\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Being recognized as the 'leader in fertility control' generates organic interest and validates the technology for new customers.\u003c\/p\u003e\n\u003cp\u003eThe company is identified as 'the leader in fertility control for managing animal pest populations and the only manufacturer of EPA-registered rodent birth control' products. Historical deployments of ContraPest® in agricultural settings demonstrated sustained success, including a confirmed 90% decline in rat activity within 12 months at one west coast egg farm. Another deployment reported an 88% improvement in pullet survival after rat population reduction.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Yes. In the niche of non-lethal fertility control, they have established category leadership.\u003c\/p\u003e\n\u003cp\u003eThe company's first product, ContraPest®, is marketed as the 'only U.S. EPA-registered contraceptive for male and female rats.' The newer Evolve® products are EPA-designated minimum risk contraceptives.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High. Brand trust and category leadership are built over time through successful deployments and media coverage.\u003c\/p\u003e\n\u003cp\u003eThe success of the Evolve® product line is a key driver, with sales growing 77% year-over-year in Q3 2025, constituting 85% of total revenue. The company ended Q3 2025 with $10.2 million in cash and short-term investments.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Yes. They actively leverage positive media coverage to reinforce their leadership position.\u003c\/p\u003e\n\u003cp\u003eThe organization reports significant growth across multiple channels, indicating successful commercialization and leveraging of their market position:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eEvolve® Rodent Birth Control product sales grew 77% year-over-year in Q3 2025.\u003c\/li\u003e\n\u003cli\u003eMunicipal revenue grew 139% year-over-year in Q3 2025 due to expanded deployments.\u003c\/li\u003e\n\u003cli\u003eRetail revenue grew 254% year-over-year in Q3 2025.\u003c\/li\u003e\n\u003cli\u003eE-commerce revenue increased 55% year-over-year in Q3 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe company achieved record quarterly revenue of $690,000 in Q3 2025, an increase of 43% from $482,000 in Q3 2024.\u003c\/p\u003e\n\u003cp\u003eThe following table details the growth metrics associated with the product adoption that reinforces category awareness:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eChannel\/Product Metric\u003c\/td\u003e\n\u003ctd\u003eYear-over-Year Growth (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003ePercentage of Total Revenue (Q3 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEvolve® Product Sales\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e77%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e85%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMunicipal Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e139%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNot Specified\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetail Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e254%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNot Specified\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eE-commerce Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e55%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNot Specified\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. First-mover advantage in establishing a new pest control paradigm is difficult to overcome.\u003c\/p\u003e\n\u003cp\u003eThe company's Q3 2025 Adjusted EBITDA loss improved to $1.2 million, a company record, compared to $1.4 million in the same quarter of the prior year. The company has 23 employees.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSenesTech, Inc. (SNES) - VRIO Analysis: International Expansion Footprint\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eInternational Expansion Footprint\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eValue: Recent expansion, such as adding a distributor in Belize, opens up new, potentially less regulated, global markets for Evolve. The addition of the \u003cstrong\u003eBelize\u003c\/strong\u003e Raptor Center as an official distributor was announced on \u003cstrong\u003eNovember 11, 2025\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eRarity: No. Many companies export, but their specific international regulatory approvals are the rare part. Approval for import and distribution in \u003cstrong\u003eBelize\u003c\/strong\u003e was secured with the support of the \u003cstrong\u003ePesticides Control Board of Belize\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eImitability: Medium. International expansion requires navigating diverse regulatory landscapes, which is a barrier, but not insurmountable.\u003c\/p\u003e\n\u003cp\u003eOrganization: Yes. The company is actively pursuing international commercialization as regulatory approvals progress.\u003c\/p\u003e\n\u003cp\u003eCompetitive Advantage: Temporary. It’s an early-stage advantage; sustained benefit depends on successfully scaling sales in those new regions.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFinance: 13-Week Cash Flow Forecast Incorporating Q3 Cash Balance\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe forecast commences with the \u003cstrong\u003e$10.2 million\u003c\/strong\u003e cash balance reported at the end of Q3 2025.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eLine Item\u003c\/th\u003e\n\u003cth\u003eWeek 1\u003c\/th\u003e\n\u003cth\u003eWeek 2\u003c\/th\u003e\n\u003cth\u003eWeek 3\u003c\/th\u003e\n\u003cth\u003eWeek 4\u003c\/th\u003e\n\u003cth\u003eWeek 5\u003c\/th\u003e\n\u003cth\u003eWeek 6\u003c\/th\u003e\n\u003cth\u003eWeek 7\u003c\/th\u003e\n\u003cth\u003eWeek 8\u003c\/th\u003e\n\u003cth\u003eWeek 9\u003c\/th\u003e\n\u003cth\u003eWeek 10\u003c\/th\u003e\n\u003cth\u003eWeek 11\u003c\/th\u003e\n\u003cth\u003eWeek 12\u003c\/th\u003e\n\u003cth\u003eWeek 13\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBeginning Cash Balance\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$10,200,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eProjected Ending Cash W1\u003c\/td\u003e\n\u003ctd\u003eProjected Ending Cash W2\u003c\/td\u003e\n\u003ctd\u003eProjected Ending Cash W3\u003c\/td\u003e\n\u003ctd\u003eProjected Ending Cash W4\u003c\/td\u003e\n\u003ctd\u003eProjected Ending Cash W5\u003c\/td\u003e\n\u003ctd\u003eProjected Ending Cash W6\u003c\/td\u003e\n\u003ctd\u003eProjected Ending Cash W7\u003c\/td\u003e\n\u003ctd\u003eProjected Ending Cash W8\u003c\/td\u003e\n\u003ctd\u003eProjected Ending Cash W9\u003c\/td\u003e\n\u003ctd\u003eProjected Ending Cash W10\u003c\/td\u003e\n\u003ctd\u003eProjected Ending Cash W11\u003c\/td\u003e\n\u003ctd\u003eProjected Ending Cash W12\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Inflows (Collections, Sales)\u003c\/td\u003e\n\u003ctd\u003eProjected Inflow W1\u003c\/td\u003e\n\u003ctd\u003eProjected Inflow W2\u003c\/td\u003e\n\u003ctd\u003eProjected Inflow W3\u003c\/td\u003e\n\u003ctd\u003eProjected Inflow W4\u003c\/td\u003e\n\u003ctd\u003eProjected Inflow W5\u003c\/td\u003e\n\u003ctd\u003eProjected Inflow W6\u003c\/td\u003e\n\u003ctd\u003eProjected Inflow W7\u003c\/td\u003e\n\u003ctd\u003eProjected Inflow W8\u003c\/td\u003e\n\u003ctd\u003eProjected Inflow W9\u003c\/td\u003e\n\u003ctd\u003eProjected Inflow W10\u003c\/td\u003e\n\u003ctd\u003eProjected Inflow W11\u003c\/td\u003e\n\u003ctd\u003eProjected Inflow W12\u003c\/td\u003e\n\u003ctd\u003eProjected Inflow W13\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Outflows (Operating Expenses, COGS)\u003c\/td\u003e\n\u003ctd\u003eProjected Outflow W1\u003c\/td\u003e\n\u003ctd\u003eProjected Outflow W2\u003c\/td\u003e\n\u003ctd\u003eProjected Outflow W3\u003c\/td\u003e\n\u003ctd\u003eProjected Outflow W4\u003c\/td\u003e\n\u003ctd\u003eProjected Outflow W5\u003c\/td\u003e\n\u003ctd\u003eProjected Outflow W6\u003c\/td\u003e\n\u003ctd\u003eProjected Outflow W7\u003c\/td\u003e\n\u003ctd\u003eProjected Outflow W8\u003c\/td\u003e\n\u003ctd\u003eProjected Outflow W9\u003c\/td\u003e\n\u003ctd\u003eProjected Outflow W10\u003c\/td\u003e\n\u003ctd\u003eProjected Outflow W11\u003c\/td\u003e\n\u003ctd\u003eProjected Outflow W12\u003c\/td\u003e\n\u003ctd\u003eProjected Outflow W13\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapital Expenditures\u003c\/td\u003e\n\u003ctd\u003eProjected CapEx W1\u003c\/td\u003e\n\u003ctd\u003eProjected CapEx W2\u003c\/td\u003e\n\u003ctd\u003eProjected CapEx W3\u003c\/td\u003e\n\u003ctd\u003eProjected CapEx W4\u003c\/td\u003e\n\u003ctd\u003eProjected CapEx W5\u003c\/td\u003e\n\u003ctd\u003eProjected CapEx W6\u003c\/td\u003e\n\u003ctd\u003eProjected CapEx W7\u003c\/td\u003e\n\u003ctd\u003eProjected CapEx W8\u003c\/td\u003e\n\u003ctd\u003eProjected CapEx W9\u003c\/td\u003e\n\u003ctd\u003eProjected CapEx W10\u003c\/td\u003e\n\u003ctd\u003eProjected CapEx W11\u003c\/td\u003e\n\u003ctd\u003eProjected CapEx W12\u003c\/td\u003e\n\u003ctd\u003eProjected CapEx W13\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDebt Payments (Principal \u0026amp; Interest)\u003c\/td\u003e\n\u003ctd\u003eProjected Debt Pmt W1\u003c\/td\u003e\n\u003ctd\u003eProjected Debt Pmt W2\u003c\/td\u003e\n\u003ctd\u003eProjected Debt Pmt W3\u003c\/td\u003e\n\u003ctd\u003eProjected Debt Pmt W4\u003c\/td\u003e\n\u003ctd\u003eProjected Debt Pmt W5\u003c\/td\u003e\n\u003ctd\u003eProjected Debt Pmt W6\u003c\/td\u003e\n\u003ctd\u003eProjected Debt Pmt W7\u003c\/td\u003e\n\u003ctd\u003eProjected Debt Pmt W8\u003c\/td\u003e\n\u003ctd\u003eProjected Debt Pmt W9\u003c\/td\u003e\n\u003ctd\u003eProjected Debt Pmt W10\u003c\/td\u003e\n\u003ctd\u003eProjected Debt Pmt W11\u003c\/td\u003e\n\u003ctd\u003eProjected Debt Pmt W12\u003c\/td\u003e\n\u003ctd\u003eProjected Debt Pmt W13\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnding Cash Balance\u003c\/td\u003e\n\u003ctd\u003eProjected Ending Cash W1\u003c\/td\u003e\n\u003ctd\u003eProjected Ending Cash W2\u003c\/td\u003e\n\u003ctd\u003eProjected Ending Cash W3\u003c\/td\u003e\n\u003ctd\u003eProjected Ending Cash W4\u003c\/td\u003e\n\u003ctd\u003eProjected Ending Cash W5\u003c\/td\u003e\n\u003ctd\u003eProjected Ending Cash W6\u003c\/td\u003e\n\u003ctd\u003eProjected Ending Cash W7\u003c\/td\u003e\n\u003ctd\u003eProjected Ending Cash W8\u003c\/td\u003e\n\u003ctd\u003eProjected Ending Cash W9\u003c\/td\u003e\n\u003ctd\u003eProjected Ending Cash W10\u003c\/td\u003e\n\u003ctd\u003eProjected Ending Cash W11\u003c\/td\u003e\n\u003ctd\u003eProjected Ending Cash W12\u003c\/td\u003e\n\u003ctd\u003eProjected Ending Cash W13\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eQ3 2025 Net Loss was \u003cstrong\u003e$1.3 million\u003c\/strong\u003e, with an Adjusted EBITDA loss of \u003cstrong\u003e$1.2 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eEvolve® Rodent Birth Control product sales grew \u003cstrong\u003e77%\u003c\/strong\u003e year-over-year in Q3 2025, representing \u003cstrong\u003e85%\u003c\/strong\u003e of total revenue.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eE-commerce revenue increased \u003cstrong\u003e55%\u003c\/strong\u003e year-over-year in Q3 2025.\u003c\/li\u003e\n\u003cli\u003eMunicipal revenue grew \u003cstrong\u003e139%\u003c\/strong\u003e year-over-year in Q3 2025.\u003c\/li\u003e\n\u003cli\u003eQ3 2025 Gross Profit Margin was \u003cstrong\u003e62.8%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516253823125,"sku":"snes-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/snes-vrio-analysis.png?v=1740214113","url":"https:\/\/dcf-model.com\/products\/snes-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}